#United States #New York #Levi & Korsinsky #Securities Fraud #Novo Nordisk

Novo Nordisk A/S Class Action Lawsuit

Overview

Novo Nordisk A/S, a leading player in the pharmaceutical industry, is currently facing a class action lawsuit over allegations of securities law violations. The case has been brought to the attention of investors through Levi & Korsinsky, LLP, a firm renowned for its expertise in securities litigation. The lawsuit primarily concerns claims of fraudulent conduct that purportedly led to significant losses for investors during a specified period in 2025.

Details of the Allegations

According to the filed complaint, Novo Nordisk is accused of making excessively optimistic declarations about its market potential while simultaneously concealing critical negative information. The timeframe in which these alleged transgressions occurred spans from May 7 to July 28, 2025. During this period, it is claimed that the company reported misleading statements related to its growth prospects, particularly related to the market for its GLP-1 medications.

This lawsuit highlights that although Novo suggested a robust growth trajectory, it failed to fully disclose challenges such as the continuing use of compounded GLP-1s and an underestimating of competition. Specifically, Novo's failure to accurately communicate the full scope of potential setbacks regarding their branded medications, such as Wegovy and Ozempic, is amongst the primary concerns cited in the lawsuit.

Impact on Investors

On July 29, 2025, following an announcement that the company would lower its sales and profit forecasts, Novo's stock suffered a notable drop. The stock plummeted about 21.83%, exchanging its closing price of $69.00 on July 28, 2025, for a significantly reduced price of $53.94 the next day. This drastic decline served as a trigger for the class action suit, as investors who faced losses sought accountability from the company.

How To Get Involved

Investors who have incurred losses during the critical timeframe are urged to take action. They have until September 30, 2025, to apply to be appointed as lead plaintiffs in the case. It’s important to note that participation in the lawsuit does not necessitate serving as a lead plaintiff for eligible investors to pursue recovery of their losses.

No Cost Involved

Class members participating in this legal action could be eligible for compensation without any upfront financial obligations. The structure of this class action lawsuit ensures that shareholders can seek justice without the burden of out-of-pocket expenses.

Why Choose Levi & Korsinsky?

With a proven track record spanning two decades, Levi & Korsinsky has successfully recovered substantial sums for investors in complicated securities cases. The firm is recognized as one of the top securities litigation firms in the United States, consistently ranked in the ISS Securities Class Action Services' Top 50 Report. Their extensive expertise and dedicated team make them a reliable partner for aggrieved shareholders in navigating the complexities of securities law.

Contact Information

For more information on how to be involved in this class action lawsuit or to discuss your rights as an investor, you can contact Levi & Korsinsky, LLP:

• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: [email protected]
• - Phone: (212) 363-7500

Through this class action, investors aim to hold Novo Nordisk accountable for the alleged securities fraud that has impacted their investments, reinforcing the importance of transparency and honesty in the financial markets.